- Home
- MFIC vs MESO Comparison
MFIC vs MESO Comparison
Compare MFIC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIC
- MESO
- Stock Information
- Founded
- MFIC 2004
- MESO 2004
- Country
- MFIC United States
- MESO Australia
- Employees
- MFIC N/A
- MESO N/A
- Industry
- MFIC Finance/Investors Services
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MFIC Finance
- MESO Health Care
- Exchange
- MFIC Nasdaq
- MESO Nasdaq
- Market Cap
- MFIC 1.1B
- MESO 861.6M
- IPO Year
- MFIC 2004
- MESO N/A
- Fundamental
- Price
- MFIC $13.69
- MESO $6.12
- Analyst Decision
- MFIC Buy
- MESO Strong Buy
- Analyst Count
- MFIC 8
- MESO 3
- Target Price
- MFIC $14.79
- MESO $11.00
- AVG Volume (30 Days)
- MFIC 386.3K
- MESO 115.7K
- Earning Date
- MFIC 11-05-2024
- MESO 09-24-2024
- Dividend Yield
- MFIC 10.92%
- MESO N/A
- EPS Growth
- MFIC 52.81
- MESO N/A
- EPS
- MFIC 1.71
- MESO N/A
- Revenue
- MFIC $277,613,000.00
- MESO $5,902,000.00
- Revenue This Year
- MFIC $11.72
- MESO $102.78
- Revenue Next Year
- MFIC $15.40
- MESO $914.87
- P/E Ratio
- MFIC $8.07
- MESO N/A
- Revenue Growth
- MFIC 7.35
- MESO N/A
- 52 Week Low
- MFIC $12.26
- MESO $1.61
- 52 Week High
- MFIC $16.36
- MESO $8.66
- Technical
- Relative Strength Index (RSI)
- MFIC 48.58
- MESO 50.76
- Support Level
- MFIC $13.31
- MESO $6.08
- Resistance Level
- MFIC $13.79
- MESO $7.04
- Average True Range (ATR)
- MFIC 0.16
- MESO 0.31
- MACD
- MFIC 0.02
- MESO 0.01
- Stochastic Oscillator
- MFIC 68.12
- MESO 47.12
About MFIC MidCap Financial Investment Corporation
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
About MESO Mesoblast Limited
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.